Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases Indian Medical PG Practice Questions and MCQs

Question 101: In antacid preparations, why is aluminum hydroxide added with a magnesium salt?

A. Magnesium causes constipation.
B. To counteract the constipating effect of aluminum hydroxide. (Correct Answer)
C. To counteract the diarrheal action of aluminum.
D. Aluminum salt causes diarrhea.

Explanation: **Explanation:** The combination of aluminum and magnesium salts in antacid preparations is a classic example of **pharmacological antagonism** used to minimize side effects [1]. **1. Why Option B is Correct:** Aluminum hydroxide is known to cause **constipation**. It does this by relaxing the smooth muscles of the gastrointestinal tract, leading to delayed gastric emptying and slower intestinal transit [1]. Conversely, magnesium salts (like magnesium hydroxide) are osmotic laxatives that cause **diarrhea** by drawing water into the intestinal lumen and increasing motility [2]. By combining both, the pro-kinetic effect of magnesium counteracts the constipating effect of aluminum, resulting in a preparation that has a neutral effect on bowel movements [1]. **2. Why Other Options are Incorrect:** * **Option A:** This is factually incorrect. Magnesium salts cause diarrhea (laxation), not constipation [2]. * **Option C & D:** These options flip the side-effect profiles of the two metals. Aluminum causes constipation, while magnesium causes diarrhea. Therefore, magnesium is added to counteract aluminum's constipation, not vice versa [1]. **NEET-PG High-Yield Pearls:** * **The "M" Rule:** **M**agnesium = **M**oves the bowels (Diarrhea); **A**luminum = **A**lts (Halts) the bowels (Constipation). * **Systemic Absorption:** While antacids are primarily local, chronic use of Aluminum hydroxide can lead to **hypophosphatemia** (as it binds phosphate in the gut), which may cause osteomalacia. * **Renal Caution:** Both aluminum and magnesium can accumulate in patients with **chronic kidney disease (CKD)**, leading to neurotoxicity or hypermagnesemia. * **Drug Interactions:** Antacids can decrease the absorption of drugs like Tetracyclines, Iron salts, and Fluoroquinolones due to chelation.

Question 102: Crofelemer is a:

A. Chloride channel activator
B. CFTR blocker (Correct Answer)
C. Somatostatin antagonist
D. Guanylate cyclase agonist

Explanation: **Explanation:** **Crofelemer** is a first-in-class antidiarrheal agent derived from the botanical latex of the *Croton lechleri* tree. 1. **Why the correct answer is right:** Crofelemer acts as a potent inhibitor of both the **Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)** chloride channel and the calcium-activated chloride channels (CaCC) on the luminal membrane of enterocytes. By blocking these channels, it reduces the secretion of chloride ions and associated water into the intestinal lumen. It is specifically FDA-approved for the symptomatic relief of **non-infectious diarrhea in patients with HIV/AIDS** on anti-retroviral therapy (ART). 2. **Why the incorrect options are wrong:** * **Chloride channel activator:** Drugs like **Lubiprostone** activate ClC-2 channels to increase fluid secretion; they are used for constipation, not diarrhea. * **Somatostatin antagonist:** There is no major clinical drug in this category for GI diseases. Conversely, Somatostatin *analogs* (e.g., **Octreotide**) are used to treat secretory diarrhea. * **Guanylate cyclase-C (GC-C) agonist:** Drugs like **Linaclotide** and **Plecanatide** stimulate GC-C to increase cGMP, leading to chloride/fluid secretion. They are used to treat Chronic Idiopathic Constipation (CIC) and IBS-C. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Luminal, non-systemic inhibition of CFTR and CaCC. * **Indication:** HIV-associated diarrhea (where ART causes secretory imbalances). * **Key Distinction:** Unlike loperamide, Crofelemer does not affect GI motility or opioid receptors, making it safer regarding constipation side effects. * **Source:** Botanical origin (*Dragon’s Blood* sap).

Question 103: Which of the following inhibit gastric secretion by blocking H2 receptors?

A. Omeprazole
B. Ranitidine (Correct Answer)
C. Sucralfate
D. Misoprostol

Explanation: Explanation: The secretion of gastric acid by parietal cells is regulated by three main secretagogues: **Histamine** (acting on H2 receptors), **Gastrin**, and **Acetylcholine** (M3 receptors) [3]. **1. Why Ranitidine is Correct:** **Ranitidine** is a competitive antagonist of the **H2 receptors** located on the basolateral membrane of parietal cells [2], [4]. By blocking these receptors, it inhibits the histamine-induced activation of adenylyl cyclase, leading to decreased intracellular cAMP levels and a significant reduction in both basal and stimulated gastric acid secretion [3]. **2. Why Other Options are Incorrect:** * **Omeprazole:** This is a **Proton Pump Inhibitor (PPI)**. It irreversibly inhibits the $H^+/K^+$ ATPase enzyme (the final common pathway of acid secretion) rather than blocking H2 receptors [1]. * **Sucralfate:** This is a **cytoprotective agent**. It polymerizes in an acidic environment (pH < 4) to form a sticky paste that binds to the ulcer base, acting as a physical barrier against acid and pepsin. It does not inhibit acid secretion. * **Misoprostol:** This is a **Prostaglandin E1 (PGE1) analogue**. It inhibits acid secretion by binding to **EP3 receptors** and also increases mucosal bicarbonate and mucus production [1]. **High-Yield Clinical Pearls for NEET-PG:** * **H2 Blockers:** Cimetidine (the prototype) is notorious for causing **gynecomastia** and being a potent **Cytochrome P450 inhibitor**. Ranitidine is preferred as it lacks these anti-androgenic effects. * **Drug of Choice:** While H2 blockers are effective, **PPIs** are the drugs of choice for GERD, Peptic Ulcer Disease, and Zollinger-Ellison Syndrome due to their superior efficacy. * **Tolerance:** H2 blockers can show "tachyphylaxis" (rapidly diminishing response) within 3-5 days of use, a phenomenon not seen with PPIs.

Question 104: A person needs to travel to Shimla the next morning. What medication should be administered to prevent motion sickness?

A. Scopolamine patch applied the night before (Correct Answer)
B. Ranitidine administered the night before and again before the trip
C. Dimenhydrinate taken one hour prior to the journey
D. Omeprazole taken thirty minutes before the trip

Explanation: ### Explanation **Correct Option: A. Scopolamine patch applied the night before** Motion sickness is caused by a mismatch between vestibular, visual, and somatosensory inputs. The vestibular system relies on **muscarinic (M1)** and **histaminergic (H1)** receptors to transmit signals to the vomiting center. **Scopolamine (Hyoscine)**, a potent anticholinergic, is the drug of choice for prophylaxis. The transdermal patch is preferred for long journeys because it provides a sustained release of the drug. It must be applied to the retroauricular (behind the ear) area **at least 4–6 hours (or the night before)** the journey to ensure therapeutic plasma concentrations are reached before the vestibular stimulus begins. **Analysis of Incorrect Options:** * **B & D (Ranitidine/Omeprazole):** These are H2-receptor antagonists and Proton Pump Inhibitors (PPIs), respectively. They reduce gastric acid secretion and are used for GERD or peptic ulcers, but they have no effect on the vestibular system or motion sickness. * **C (Dimenhydrinate):** While H1-antihistamines like Dimenhydrinate are effective for motion sickness, they have a short duration of action. Taking it only one hour prior may be effective for short trips, but for a long journey (like traveling to a hill station), the Scopolamine patch is superior due to its 72-hour efficacy and prophylactic steady-state levels. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Scopolamine blocks M1 receptors in the vestibular apparatus and the nucleus tractus solitarius. * **Timing is Key:** Antiemetics for motion sickness are **prophylactic**; they are ineffective once vomiting has started. * **Side Effects:** Common anticholinergic effects include dry mouth, blurred vision (cycloplegia), and sedation. * **Alternative:** For acute/short-term prophylaxis, **Promethazine** or **Cyclizine** (H1 blockers) can be used.

Question 105: Which of the following is the best medical treatment for GERD?

A. H2 blocking agents
B. Proton pump inhibitors (PPIs) (Correct Answer)
C. Sucralfate
D. Prokinetic agents

Explanation: ### Explanation **Correct Option: B. Proton pump inhibitors (PPIs)** **Why PPIs are the best treatment:** Proton Pump Inhibitors (e.g., Omeprazole, Pantoprazole) are the **gold standard** and most effective medical treatment for Gastroesophageal Reflux Disease (GERD). They work by irreversibly inhibiting the **H+/K+ ATPase pump** (the final common pathway of acid secretion) in the gastric parietal cells. Compared to other agents, PPIs provide superior symptomatic relief, achieve faster healing of erosive esophagitis, and maintain remission more effectively. **Analysis of Incorrect Options:** * **A. H2 blocking agents (e.g., Ranitidine):** These inhibit only the histamine-stimulated pathway of acid secretion. While useful for mild or intermittent symptoms, they are less potent than PPIs and are prone to **tachyphylaxis** (rapidly diminishing response), making them inferior for long-term GERD management. * **C. Sucralfate:** This is a mucosal protective agent that requires an acidic environment to form a paste-like complex. It does not reduce acid production and is generally ineffective as a monotherapy for GERD. * **D. Prokinetic agents (e.g., Metoclopramide, Itopride):** These increase Lower Esophageal Sphincter (LES) tone and gastric emptying. While they address the pathophysiology of reflux, their efficacy is low and they carry significant side effects (e.g., extrapyramidal symptoms), making them only adjunctive treatments. **High-Yield Clinical Pearls for NEET-PG:** * **Timing:** PPIs should be taken **30–60 minutes before the first meal** of the day for maximal efficacy (when the number of H+/K+ ATPase pumps is highest). * **DOC:** PPIs are the Drug of Choice for GERD, Peptic Ulcer Disease, and **Zollinger-Ellison Syndrome**. * **Long-term risks:** Chronic PPI use is associated with Vitamin B12 deficiency, hypomagnesemia, increased risk of *C. difficile* infections, and osteoporotic fractures.

Question 106: Antiemetic effect of metoclopramide is mainly due to its action as:

A. 5HT3 antagonist
B. D2 antagonist (Correct Answer)
C. M3 antagonist
D. 5HT4 agonist

Explanation: **Explanation:** **Metoclopramide** is a substituted benzamide used as a prokinetic and antiemetic. Its primary mechanism for the **antiemetic effect** is the blockade of **D2 receptors** in the Chemoreceptor Trigger Zone (CTZ) of the medulla. By antagonizing these receptors, it raises the threshold of the CTZ and prevents the activation of the vomiting center. **Analysis of Options:** * **B. D2 Antagonist (Correct):** This is the predominant mechanism for its central antiemetic action. It also acts peripherally to increase Lower Esophageal Sphincter (LES) tone and promote gastric emptying (prokinetic effect) by antagonizing D2 receptors which normally inhibit ACh release. * **A. 5HT3 Antagonist:** While metoclopramide has weak 5HT3 antagonistic properties, this only contributes to its antiemetic effect at very high doses (e.g., in chemotherapy-induced vomiting). It is not its *main* mechanism. * **C. M3 Antagonist:** Metoclopramide does not block M3 receptors; in fact, it indirectly enhances cholinergic activity to promote GI motility. * **D. 5HT4 Agonist:** Metoclopramide does act as a 5HT4 agonist, but this action is primarily responsible for its **prokinetic effect** (increasing intestinal motility) rather than its central antiemetic effect. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** Due to D2 blockade in the nigrostriatal pathway, it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia and akathisia (especially in children). It also causes **hyperprolactinemia** (leading to gynecomastia/galactorrhea). * **Drug of Choice:** It is often used for gastroparesis (e.g., diabetic gastroparesis) and as an adjunct in gastrointestinal radiology. * **Contraindication:** It should never be used in cases of **mechanical GI obstruction** or pheochromocytoma.

Question 107: Misoprostol is a:

A. Prostaglandin E1 analogue (Correct Answer)
B. Prostaglandin E2 analogue
C. Prostaglandin antagonist
D. Antiprogestin

Explanation: **Explanation:** **Misoprostol** is a synthetic **Prostaglandin E1 (PGE1) analogue** [1]. In the gastrointestinal tract, it acts on parietal cells to inhibit gastric acid secretion and enhances mucosal defense by increasing bicarbonate and mucus production [3]. **Why the correct answer is right:** * **Option A (PGE1 analogue):** Misoprostol mimics the cytoprotective effects of natural PGE1 [5]. It is specifically FDA-approved for the **prevention of NSAID-induced gastric ulcers**, as NSAIDs inhibit cyclooxygenase (COX) enzymes, leading to a deficiency of endogenous prostaglandins [1]. **Why the incorrect options are wrong:** * **Option B (PGE2 analogue):** While PGE2 (e.g., Dinoprostone) also has cytoprotective properties, Misoprostol is chemically classified as a PGE1 derivative [5]. * **Option C (Prostaglandin antagonist):** Misoprostol is an **agonist** at prostaglandin receptors (EP receptors), not an antagonist. * **Option D (Antiprogestin):** This describes **Mifepristone (RU-486)**. While Misoprostol is often used *in combination* with Mifepristone for medical abortion (due to its uterine-contracting effects), it is not an antiprogestin itself [4]. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice:** Misoprostol is the specific drug of choice for preventing NSAID-induced ulcers, though Proton Pump Inhibitors (PPIs) are more commonly used in clinical practice due to better tolerability. 2. **Obstetric Use:** It is used for cervical ripening, induction of labor, and management of Postpartum Hemorrhage (PPH) [2]. 3. **Contraindication:** It is strictly **contraindicated in pregnancy** (unless used for legal termination) because it is a potent uterine stimulant and can cause abortion [4]. 4. **Side Effects:** The most common side effect is **diarrhea** and abdominal cramps [4].

Question 108: Which antiemetic phenothiazine with labyrinthine suppressant activity is used for vertigo?

A. Prochlorperazine (Correct Answer)
B. Cinnarizine
C. Hyoscine
D. Promethazine

Explanation: **Explanation:** **Prochlorperazine** (Option A) is the correct answer. It is a piperazine-side chain phenothiazine that acts primarily as a D2-receptor antagonist in the Chemoreceptor Trigger Zone (CTZ). Unlike many other phenothiazines, it possesses significant **labyrinthine suppressant** properties. It is specifically indicated for the control of vertigo associated with Meniere’s disease, labyrinthitis, and vestibular disorders, in addition to its use as a potent antiemetic. **Analysis of Incorrect Options:** * **B. Cinnarizine:** While this is a drug of choice for motion sickness and vertigo, it is an **antihistamine (H1 blocker)** with calcium channel blocking activity, not a phenothiazine. * **C. Hyoscine (Scopolamine):** This is an **anticholinergic** drug. It is the most effective agent for the *prophylaxis* of motion sickness but lacks the phenothiazine structure and is not primarily used for vestibular vertigo. * **D. Promethazine:** This is a phenothiazine, but it is classified primarily as a **sedative-antihistamine**. While it is used for motion sickness due to its anticholinergic and H1-blocking effects, Prochlorperazine is the specific phenothiazine preferred for its superior labyrinthine suppressant activity in clinical vertigo. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for Motion Sickness:** Hyoscine (prophylactic). * **DOC for Vertigo (Acute attack):** Prochlorperazine or Cinnarizine. * **Side Effects:** As a D2 blocker, Prochlorperazine can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia, especially in children and young adults. * **Mechanism in Vertigo:** It suppresses the vestibular apparatus by inhibiting the trigger impulses from the semicircular canals to the vomiting center.

Question 109: Which NK receptor antagonist prevents vomiting?

A. Bosutran
B. Gramisetron
C. Ondansetron
D. Aprepitant (Correct Answer)

Explanation: **Explanation:** **1. Why Aprepitant is Correct:** Aprepitant is a selective, high-affinity antagonist of **Neurokinin-1 (NK1) receptors** in the area postrema and the nucleus tractus solitarius. Substance P is the endogenous ligand for these receptors; by blocking its binding, Aprepitant effectively inhibits the emetic reflex. It is particularly effective for the **delayed phase** of chemotherapy-induced nausea and vomiting (CINV) and is often used in a triple regimen with a 5-HT3 antagonist and a corticosteroid (Dexamethasone). **2. Why the Other Options are Incorrect:** * **Bosentan (likely intended by "Bosutran"):** This is an antagonist of **Endothelin receptors** (ET-A and ET-B), used primarily in the treatment of Pulmonary Arterial Hypertension (PAH). It has no antiemetic properties. * **Granisetron & Ondansetron:** These are potent **5-HT3 receptor antagonists**. While they are first-line agents for preventing vomiting, they act on serotonin receptors, not NK receptors. They are most effective for the **acute phase** of CINV (within 24 hours). **3. High-Yield Clinical Pearls for NEET-PG:** * **NK1 Antagonists:** Include Aprepitant (oral), Fosaprepitant (IV prodrug), and Rolapitant (long half-life). * **Metabolism:** Aprepitant is metabolized by **CYP3A4**; it can increase plasma levels of drugs like Dexamethasone and Warfarin. * **Drug of Choice:** NK1 antagonists are the drug of choice for highly emetogenic chemotherapy (e.g., Cisplatin-based regimens). * **Netupitant:** A newer NK1 antagonist often available in a fixed-dose combination with Palonosetron (a 2nd gen 5-HT3 antagonist).

Question 110: What is the primary mechanism of action of metoclopramide?

A. Increases the tone of the lower esophageal sphincter (Correct Answer)
B. Decreases gastric acid secretion
C. Increases gastric peristalsis
D. Acts as an ulcer healing agent

Explanation: **Metoclopramide** is a substituted benzamide that acts as a potent **prokinetic agent**. Its primary mechanism of action involves **D2-receptor antagonism** and **5-HT4 receptor agonism** in the gastrointestinal tract [1].1. **Why Option A is Correct:** Metoclopramide increases the release of acetylcholine from the myenteric plexus [1]. This leads to an **increase in the resting tone of the Lower Esophageal Sphincter (LES)** and enhances the amplitude of esophageal contractions [1]. This effect is clinically vital for preventing gastroesophageal reflux.2. **Why Other Options are Incorrect:** * **Option B:** Metoclopramide has no direct effect on parietal cells or the H+/K+ ATPase pump; therefore, it does not decrease gastric acid secretion [2]. * **Option C:** While metoclopramide *does* increase gastric peristalsis (prokinetic effect), the question asks for the "primary" or most characteristic physiological change associated with its use in conditions like GERD. In many standardized exams, the strengthening of the LES is highlighted as its hallmark physiological action. * **Option D:** It is not a cytoprotective agent or an H2 blocker/PPI; it does not promote the healing of peptic ulcers directly.**High-Yield NEET-PG Pearls:** * **Dual Action:** It is a D2 antagonist (central and peripheral) and a 5-HT4 agonist (peripheral) [1]. At high doses, it also acts as a 5-HT3 antagonist (anti-emetic).* **Clinical Use:** Drug of choice for **Diabetic Gastroparesis** and as an anti-emetic in chemotherapy [2].* **Side Effects:** Because it crosses the Blood-Braine Barrier (BBB), it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia and Parkinsonism, and hyperprolactinemia (leading to gynecomastia/galactorrhea).* **Contraindication:** Never use in cases of **mechanical GI obstruction** or pheochromocytoma.

Practice by Chapter

Acid-Peptic Disease Therapeutics

Practice Questions

Proton Pump Inhibitors

Practice Questions

H2 Receptor Antagonists

Practice Questions

Antacids and Mucosal Protectants

Practice Questions

Antiemetics

Practice Questions

Prokinetic Agents

Practice Questions

Laxatives and Purging Agents

Practice Questions

Antidiarrheal Drugs

Practice Questions

Drugs for Inflammatory Bowel Disease

Practice Questions

Pancreatic Enzyme Supplements

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free